Phase 3 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose stomach cancer or cancer at the junction of the stomach and oesophagus has been confirmed by laboratory testing of tissue or cell samples
• People who have had major surgery (including removal of nearby lymph nodes, known as D2 dissection) at the trial centre, and whose cancer was found to be at stage III after surgery
• People whose imaging scans show no clear signs that the cancer has come back or spread
• People aged between 18 and 75 years old
• People who are physically well enough to carry out light daily activities (this is measured using a standard health scale called the ECOG score, where a score of 0 or 1 is required)
• People whose blood test results show their body can tolerate chemotherapy
• People whose blood counts meet specific minimum levels — including white blood cells, red blood cells, platelets, and other markers — and who show no signs of a bleeding tendency
• People whose liver and kidney function tests fall within acceptable ranges, as shown by specific blood chemistry results

Who may not be able to join:

• People whose cancer is a type other than adenocarcinoma (a specific type of cancer cell)
• People who are pregnant or currently breastfeeding
• People who have had another type of cancer in the past 5 years
• People with a history of uncontrolled epilepsy, a brain or nervous system condition, or a psychiatric disorder that the trial doctor believes would prevent them from giving informed consent or following the treatment plan
• People with serious active heart problems, such as significant heart failure, a heart rhythm problem requiring medication, or a heart attack within the past 12 months
• People with serious complications from diabetes, such as kidney damage caused by diabetes or dangerous changes in blood sugar chemistry
• People with a blockage in the digestive tract, a physical abnormality affecting digestion, or a condition that reduces the body's ability to absorb medication properly, which could affect how the study drug (S-1) is absorbed
• People who have had bleeding in the digestive tract within the past two weeks, or who the trial doctor considers to be at high risk of bleeding
• People with pre-existing nerve damage in the hands or feet (peripheral neuropathy) at a level above a very minor threshold, with a specific exception noted for those with reduced deep tendon reflexes only (confirm with trial site)
• People who need immunosuppressive medication following an organ transplant
• People who have already received a different chemotherapy treatment
• People with uncontrolled serious infections or other significant ongoing medical conditions
• People who are known to be allergic to S-1 or any of the other components used in the study treatment

Important: Always verify eligibility with the trial site directly before applying.